行情

UTHR

UTHR

联合治疗
NASDAQ

实时行情|Nasdaq Last Sale

106.92
+0.94
+0.89%
已收盘, 16:41 02/19 EST
开盘
106.41
昨收
105.98
最高
107.83
最低
106.24
成交量
39.14万
成交额
--
52周最高
128.94
52周最低
74.31
市值
46.92亿
市盈率(TTM)
-48.5008
分时
5日
1月
3月
1年
5年

分析师评级

11位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

UTHR 新闻

  • Earnings Preview: United Therapeutics (UTHR) Q4 Earnings Expected to Decline
  • Zacks.18小时前
  • Zacks.com featured highlights include: Tempur Sealy International, Twin River Worldwide, Rite Aid, DaVita and United Therapeutics
  • Zacks.20小时前
  • United Therapeutics Corporation to Report Fourth Quarter and Full Year 2019 Financial Results Before the Market Opens on Wednesday, February 26, 2020
  • PR Newswire.1天前
  • 5 Stocks in Focus on Remarkable Relative Price Strength
  • Zacks.1天前

更多

所属板块

生物技术和医学研究
+1.01%
制药与医学研究
+0.22%

热门股票

名称
价格
涨跌幅

UTHR 简况

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). The Company markets and sells an oncology product in the United States, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of neuroblastoma. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies.
展开

Webull提供United Therapeutics Corporation的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。